Detailed Information on Publication Record
2017
Tamoxifen-Dependent Induction of AGR2 Is Associated with Increased Aggressiveness of Endometrial Cancer Cells.
HRSTKA, Roman, Ján PODHOREC, Rudolf NENUTIL, Lucia SOMMEROVÁ, Joanna Agnieszka OBACZ et. al.Basic information
Original name
Tamoxifen-Dependent Induction of AGR2 Is Associated with Increased Aggressiveness of Endometrial Cancer Cells.
Authors
HRSTKA, Roman, Ján PODHOREC, Rudolf NENUTIL, Lucia SOMMEROVÁ, Joanna Agnieszka OBACZ, Michal ĎURECH, Jakub FAKTOR, Pavel BOUCHAL, Hana SKOUPILOVÁ and Bořivoj VOJTĚŠEK
Edition
Cancer Investigation, Marcel Dekker, 2017, 0735-7907
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 2.053
Organization unit
Faculty of Science
UT WoS
000401553900003
Keywords in English
AGR2; Breast cancer; Endometrial cancer; Tamoxifen
Tags
Tags
International impact, Reviewed
Změněno: 24/4/2019 14:16, Mgr. Tereza Miškechová
Abstract
V originále
Tamoxifen treatment in breast cancer patients is associated with increased risk of endometrial malignancies. Significantly, higher AGR2 expression was found in endometrial cancers that developed in women previously treated with tamoxifen compared to those who had not been exposed to tamoxifen. An association of elevated AGR2 level with myometrial invasion occurrence and invasion depth was also found. In vitro analyses identified a stimulatory effect of AGR2 on cellular proliferation. Although adverse tamoxifen effects on endometrial cells remain elusive, our work identifies elevated AGR2 as a candidate tamoxifen-dependent mechanism of action responsible for increased incidence of endometrial cancer.
Links
GA17-05957S, research and development project |
|